Sarepta investors, analysts shrug off E.U. setback for Duchenne drug
September 21, 2018 at 12:01 PM EDT
European approval of the drug "is a matter of 'when' not 'if,'" according to one analyst note.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|